radiographic evidence of acute pancreatitis ( Figure 1 ). Figure 1. Study flow diagram. Abbreviations: FOLFIRINOX, 5-fluorouracil/leucovorin/oxaliplatin/irinotecan; Gem/Nab-paclitaxel, gemcitabine + nanoparticle albumin–bound paclitaxel; PDAC
Search Results
Caitlin A. Hester, Giampaolo Perri, Laura R. Prakash, Jessica E. Maxwell, Naruhiko Ikoma, Michael P. Kim, Ching-Wei D. Tzeng, Brandon Smaglo, Robert Wolff, Milind Javle, Michael J. Overman, Jeffrey E. Lee, and Matthew H.G. Katz
Ryan D. Gentzler and Jyoti D. Patel
became available for the treatment of NSCLC. The large phase III ECOG 1594 trial randomized 1155 patients with advanced NSCLC with a performance status (PS) of 0 to 2 to a reference regimen of cisplatin and paclitaxel versus 3 other platinum
Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi, and Kathryn J. Ruddy
This study analyzed preexisting, deidentified data, and was therefore deemed exempt from Institutional Review Board approval. Study Population We identified patients who initiated AC, TAC (paclitaxel or docetaxel with doxorubicin and
Kim Margolin
Einhorn LH . Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group . J Clin Oncol 2002 ; 20 : 1859 – 1863 . 18 Hartmann JT Schleucher N Metzner B . Phase I
David H. Moore
. Moore DH Blessing JA McQuellon RP . Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol 2004 ; 22 : 3113 – 3119
Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong
, patients received an average of 5 chemotherapy treatments (range, 2–6), with an average relative dose intensity of 91.8% for carboplatin and 86.7% for paclitaxel. During the STRENGTH period, patients received an average of 6 (range, 5–8) chemotherapy
Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell
only due to smaller sample sizes. The RR of a dose reduction or delay for doxorubicin, docetaxel, and paclitaxel was assessed independently. Cyclophosphamide was not assessed because it was exclusively administered concurrent to doxorubicin or docetaxel
paclitaxel (Taxol, Bristol-Myers Squibb Company) as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness
Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan
alone (CH arm: n=182) or with bevacizumab (BEV + CH arm: n=179). 11 Chemotherapy included paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan. Adding bevacizumab to chemotherapy significantly improved PFS, with a median PFS of 6.7 months (95
Amit Mahipal, Minsig Choi, and Richard Kim
to poor accrual. In the 40 patients studied, survival was significantly longer in the irinotecan arm (median OS, 4.0 vs 2.4 months). Tumor-related symptoms were significantly improved in the experimental arm. Other single agents, such as paclitaxel
